Story · Medicine & Biotech

Katy Beckermann: ENZARAD Finds No Overall Metastasis-Free Survival Benefit With Enzalutamide

1 outlet · first reported by OncoDaily on

Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared on X: “High-risk prostate cancer on RT plus 2 yrs of ADT: 2 yrs of enzalutamide did no (OncoDaily)